Until now, the CellSearch® system (for enumeration of EpCAM-positive CTCs in CRPC) and the FoundationOne LiquidTM CDx (for profiling BRCA1 and/or BRCA2 mutations in ctDNA in mCRPC patients) stand as the sole FDA-approved or cleared blood-based liquid biopsy tests for PCa. The gene discussed is BRCA1; the disease is posterior cortical atrophy.